A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Umoja Biopharma
Umoja Biopharma
OHSU Knight Cancer Institute
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
M.D. Anderson Cancer Center